Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
- Conditions
- Brain and Central Nervous System TumorsCognitive/Functional EffectsNeurotoxicitySolid Tumor
- Interventions
- Procedure: cognitive assessmentProcedure: quality-of-life assessmentRadiation: radiation therapy
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00469937
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
- Conditions
- LymphomaSolid Tumor
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00470405
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
- Conditions
- Liver Cancer
- Interventions
- Procedure: quality-of-life assessmentRadiation: yttrium Y 90 resin microspheres
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00469963
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
- Conditions
- Colorectal Cancer
- Interventions
- Biological: cetuximabGenetic: proteomic profilingOther: immunohistochemistry staining methodOther: laboratory biomarker analysisOther: mass spectrometry
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00466505
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: bevacizumabGenetic: fluorescence in situ hybridizationGenetic: gene expression analysisOther: immunologic techniqueOther: laboratory biomarker analysisProcedure: biopsy
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00466687
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00467116
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
- Conditions
- PheochromocytomaHead and Neck CancerIslet Cell TumorMetastatic Cancer
- Interventions
- Radiation: yttrium Y 90 resin microspheres
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00466856
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00425750
- Locations
- 🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
🇺🇸MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States
🇺🇸Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00416650
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Genetic: protein expression analysisOther: laboratory biomarker analysisProcedure: biopsyProcedure: conventional surgeryProcedure: neoadjuvant therapy
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00343512
- Locations
- 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States